drugset / Trial / NCT01406119

An Extension Study of ABT-806 in Subjects With Advanced Solid Tumors

NCT01406119

Phase 1 Completed 14 enrolled AbbVie
NaSingle-groupOpen-labelTreatment

Summary

This is an extension study of ABT-806 for subjects with advanced solid tumors.

Timeline

Start
2011-10
Primary completion
2017-01
Completion
2017-01

Drugs

EvaluationDrugModalityDoseRoute
Subject DEPATUXIZUMAB Monoclonal antibody Intravenous

Indications